# Pembrolizumab in Ultramutated and Hypermutated Endometrial Cancer

> **NCT02899793** · PHASE2 · COMPLETED · sponsor: **Yale University** · enrollment: 25 (actual)

## Conditions studied

- Recurrent Endometrial Cancer

## Interventions

- **DRUG:** Pembrolizumab

## Key facts

- **NCT ID:** NCT02899793
- **Lead sponsor:** Yale University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-09
- **Primary completion:** 2024-07-17
- **Final completion:** 2024-07-17
- **Target enrollment:** 25 (ACTUAL)
- **Last updated:** 2025-06-11

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02899793

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02899793, "Pembrolizumab in Ultramutated and Hypermutated Endometrial Cancer". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT02899793. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*